BioCardia to Present at Dawson James Securities 5th Annual Small Cap Growth Conference
October 28 2019 - 8:00AM
BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of
comprehensive solutions for cardiovascular regenerative therapies,
today announced that company CEO Peter Altman, PhD, is scheduled to
present at the Dawson James Securities Small Cap Growth Conference
on Tuesday, October 29, 2019, at 4:30pm EST in Preserve Ballroom C
at the Wyndham Grand Hotel in Jupiter, Florida.
To view a live webcast and subsequent archived
recording of the presentation, please visit the BioCardia website
by clicking here.
About BioCardia®BioCardia,
Inc., headquartered in San Carlos, California, is developing
regenerative biologic therapies to treat cardiovascular disease.
CardiAMP™ and CardiALLO™ cell therapies are the Company’s
biotherapeutic product candidates in clinical development. The
Company's current products include the Helix™ Biotherapeutic
Delivery System and the Morph® steerable guide and sheath catheter
portfolio, including the new AVANCE™ Steerable Introducer family.
BioCardia also partners with other biotherapeutic companies to
provide its Helix systems and clinical support to their programs
studying therapies for the treatment of heart failure, chronic
myocardial ischemia and acute myocardial infarction.
About Dawson James
SecuritiesDawson James Securities, Inc., a member of
FINRA/SIPC, is a full-service investment bank headquartered in Boca
Raton, FL. http://www.dawsonjames.com.
Forward Looking Statements This
press release contains forward-looking statements that are subject
to many risks and uncertainties. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations. Such factors include, among
others, the inherent uncertainties associated with developing new
products or technologies, regulatory approvals, unexpected
expenditures, the ability to raise the additional funding needed to
continue to pursue BioCardia’s business and product development
plans and overall market conditions. These forward-looking
statements are made as of the date of this press release, and
BioCardia assumes no obligation to update the forward-looking
statements.
We may use terms such as “believes,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should,” “approximately” or other words that
convey the uncertainty of future events or outcomes to identify
these forward-looking statements. Although we believe that we have
a reasonable basis for each forward-looking statement contained
herein, we caution you that forward-looking statements are not
guarantees of future performance and that our actual results, and
the development of the industry in which we operate may differ
materially from the forward-looking statements contained in this
presentation. As a result of these factors, we cannot assure you
that the forward-looking statements in this press release will
prove to be accurate. Additional factors that could materially
affect actual results can be found in BioCardia’s
Form 10-Q filed with the Securities and Exchange
Commission on August 9, 2019, including under the caption titled
“Risk Factors.” BioCardia expressly disclaims any intent or
obligation to update these forward-looking statements, except as
required by law.
INVESTOR CONTACT: David McClung,
Chief Financial Officer investors@BioCardia.com (650) 226-0120
MEDIA CONTACT: Michelle McAdam,
Chronic Communications, Inc. michelle@chronic-comm.com (310)
902-1274
BioCardia (NASDAQ:BCDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioCardia (NASDAQ:BCDA)
Historical Stock Chart
From Apr 2023 to Apr 2024